Healthcare Industry News:  Accuray 

Devices Oncology

 News Release - April 4, 2006

Sinai Hospital of Baltimore Acquires Second CyberKnife(R) System to Support Rapid Growth in Extracranial Tumor Treatments

Extracranial Procedures With the CyberKnife System Increase by More Than 230 Percent Over First Year of Operation

SUNNYVALE, Calif., April 4 (HSMN NewsFeed) -- Accuray Incorporated, the global leader in the field of robotic radiosurgery, announced today that Sinai Hospital of Baltimore acquired its second CyberKnife Robotic Radiosurgery System for its expanding CyberKnife center. The addition of the new CyberKnife System supports the center's recent growth in extracranial procedures, led in large part by the growth in radiosurgical lung tumor treatments. Like Sinai's first CyberKnife System installed in 2003, its second was acquired through Accuray's Placement Program, a unique relationship that supports hospitals' acquisition of this advanced robotic radiosurgery technology. All radiosurgery procedures at Sinai Hospital are performed exclusively with the CyberKnife Robotic Radiosurgery System.

"Adding a second CyberKnife System to our center enables Sinai Hospital to meet the increasing demand we're seeing for the treatment of extracranial tumors -- especially those that are inoperable or surgically complex," said Neil Meltzer, president of Sinai Hospital. "We are excited to continue our relationship with Accuray and offer our patients this revolutionary, noninvasive procedure which allows doctors to treat tumors anywhere in the body."

In 2005, supported by the Accuray's Placement Program, Sinai Hospital's first CyberKnife System achieved a more than 230 percent increase in extracranial procedures over its first year in operation. The increase was largely driven by lung tumor procedures, which grew more than 40 times over the same period.

"Sinai's use of the CyberKnife System to treat a growing number of extracranial tumors reflects a trend we are seeing worldwide. In fact, today extracranial tumor treatment now represents more than 50 percent of all procedures performed with the CyberKnife System in the United States," said Eric Lindquist, chief marketing officer for Accuray. "To help hospitals meet the growing demand for technology that can treat complex tumors anywhere in the body, we, at Accuray, are committed to providing industry-leading business service solutions, which ensure that the acquisition of the CyberKnife System can become a reality for more institutions."

Unique to the industry, the Accuray Placement Program provides business development options designed to support hospitals' acquisition of CyberKnife Systems as well as financing, reimbursement, operational, technical and upgrade support services throughout the life of the System.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife System is the world's first and only commercially available intelligent robotic radiosurgery system designed to treat tumors anywhere in the body. The CyberKnife System treats patients in single or staged (typically 2-5) sessions by precisely delivering multiple beams of radiation at a tumor while minimizing injury to surrounding healthy tissue. Image guidance and computer controlled robotics combine to continuously track, detect and correct for tumor and patient movement throughout the treatment with sub-millimeter accuracy. Because of this extreme precision and accuracy, no head or body frame is required. The CyberKnife System has attracted a new patient population to a physician's practice and complements existing radiation therapy, IMRT or IGRT programs.

About Accuray

Accuray Inc., a privately held company based in Sunnyvale, Calif., is the global leader in the field of robotic radiosurgery. Its CyberKnife System is the world's first and only intelligent robotic radiosurgery system designed to treat tumors anywhere in the body with sub-millimeter accuracy. More than 100 CyberKnife Systems have been acquired by leading medical centers throughout the world. To date, the CyberKnife has treated more than 18,000 patients worldwide. For more information, please visit

For media inquiries, please contact Jeff Speer at or 310-577-7870, ext. 156.

©2006 Accuray Incorporated. All rights reserved. Accuray, the Accuray logo, CyberKnife, Synchrony, Xsight and CyRIS are among trademarks or registered trademarks of Accuray Incorporated.

Source: Accuray

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.